Testing Laboratories and Services (U.S., NAICS 541380)

1. Overview

Testing laboratories are the independent referees of the physical economy. When a water utility must prove its supply is safe, when a builder must certify that concrete will bear a load, when a manufacturer must show a battery will not catch fire, or when a pipeline operator must confirm a weld has not cracked, a third-party lab runs the measurement and issues a defensible result. The work is unglamorous, deeply embedded in law and contracts, and — because most of it is required rather than optional — remarkably steady.

The North American Industry Classification System (NAICS) code 541380 covers establishments that perform physical, chemical, and other analytical testing as a service to others: environmental testing (soil, water, air), materials and mechanical testing, geotechnical (soil-and-foundation) testing, calibration, electrical and electronic testing, and non-destructive testing, or NDT (inspecting a part without damaging it). The measurement can happen in a fixed laboratory or on-site.[4] The U.S. commercial slice of this industry generated roughly $27.9 billion in receipts and employed about 158,000 people across some 7,500 establishments run by around 5,700 firms.[1][2]

Why it matters to an investor: demand is largely non-discretionary and regulation-driven, the work is sticky and repeat-based, margins are healthy, and the industry is extraordinarily fragmented — a textbook setup for "buy-and-build" consolidation. The investment case is strongest where testing is recurring, technically specialized, accredited, and hard to bring in-house; it is weaker where work is discretionary, easily replicated, or tied to cyclical industrial projects. Direct public-market exposure is thin and mostly foreign, while private markets host one of the most active roll-up sectors in business services, with thousands of small independent labs still to be acquired.

2. What it is and how it's structured

Scope. NAICS 541380 comprises firms primarily engaged in providing testing as a service — "physical, chemical, and other analytical testing." It explicitly spans acoustics/vibration testing, assaying, biological testing (except medical and veterinary), calibration, electrical and electronic testing, geotechnical testing, mechanical testing, non-destructive testing, and thermal testing.[4]

Typical customers include:

• Manufacturers seeking product qualification, quality control, or regulatory approval
• Pharmaceutical, biotechnology, and medical-device companies
• Food, agriculture, and consumer-product companies
• Utilities, engineering firms, and environmental consultants
• Aerospace, defense, energy, mining, and infrastructure operators
• Government agencies and research institutions

What it excludes (this matters for sizing the industry):

• Medical and diagnostic labs — blood work, pathology — sit in NAICS 621511, not here.[4]
• Veterinary testing is NAICS 541940.[4]
• Automobile emissions inspection is NAICS 811198.[4]
• Analytical-instrument manufacturing and much research and development (NAICS 541715) are separate codes.[4]
• Related work that often lives next door: environmental consulting (NAICS 541620) and engineering services including some materials work (NAICS 541330). Large "testing, inspection and certification" (TIC) companies routinely book revenue across several of these codes at once — one reason no single statistic captures them cleanly.

Ownership mix. The industry is overwhelmingly privately held, and the federal data carry no legal-form or ownership breakdown, so ownership must be read from company research, not inferred from the totals. The typical establishment has about 21 employees[1] — these are real payroll businesses, not one-person shops — but the ownership spectrum is wide:

• Publicly traded global TIC companies
• Private-equity-backed laboratory platforms (e.g., Element Materials Technology, Pace Analytical)
• Founder- or family-owned regional laboratories
• Foundation- or association-owned testing groups (DNV, the TÜV bodies, DEKRA, NSF)
• Corporate in-house, university, and government laboratories

Government and academic labs (the Environmental Protection Agency, U.S. Department of Agriculture, state public-health and environmental labs, national laboratories, universities) and manufacturers' own quality-control labs do enormous volumes of testing but are not counted in 541380 because they are not selling testing as a commercial service.

3. How big it is

These are the ground-truth federal figures. They come from different Census programs and years and should not be treated as one perfectly synchronized market-size series.

That works out to roughly $75,000 in average annual pay per worker[1] — a skilled, well-compensated workforce of chemists, technicians, and engineers — and the $19 million small-business ceiling set by the U.S. Small Business Administration (SBA) tells you the government treats even fairly sizable labs as "small" for federal-contracting set-asides.[3] That ceiling is a contracting classification, not an estimate of industry size.

The undercount caveat. The $27.9 billion figure is the independent commercial market only. The Economic Census generally covers establishments with paid employees and excludes government-operated businesses; County Business Patterns also excludes the self-employed and most government employees.[5] Total testing activity in the U.S. economy is far larger and split across buckets the 541380 count misses: testing performed inside manufacturers' own facilities (counted under the parent's manufacturing code), government and university labs, and TIC-firm revenue booked under adjacent engineering and consulting codes. That is why third-party market-research estimates of the broader U.S. TIC market run much higher — commonly in the $50–70 billion range for 2024–2025, depending on how much inspection and certification each analyst folds in.[6] Treat the federal number as the reliable floor for the pure-testing core, and the market-research numbers as the wider TIC bundle. Unlike some service industries, 541380 is not badly distorted by tiny one-person operators; it is a genuine employer industry.

4. The investable universe

There are only a few ways to own this industry through public equities, and most of the largest operators are listed outside the United States. None is a pure-play proxy for U.S. NAICS 541380 revenue — each combines testing with inspection, certification, advisory, software, or non-U.S. operations. Figures below are company-wide (global) revenue for the most recent full year available, not U.S.-only.

U.S.-listed:

Foreign-listed global majors (reachable by U.S. investors via American Depositary Receipts (ADRs) or over-the-counter lines):

Major private / PE-owned platforms and owner-operators:

Bottom line: pure-play public exposure is thin and mostly foreign; the deepest and most active opportunity set is in private markets.

5. How the money works

A testing lab's economics look like a hybrid of a factory and a professional-services firm.

Revenue is built from two engines: sample volume × price per test (a bench-based analytical lab charging per water or food sample) and billable hours × utilization (a field crew of NDT or geotechnical technicians on a job site). Pricing rises with technical complexity, turnaround speed, required accreditation, method validation, chain-of-custody demands, and the cost of failure for the customer. The metrics owners actually watch:

• Sample throughput and turnaround time — how many analyses a lab pushes through, and how fast. Faster turnaround commands premium pricing.
• Capacity / technician utilization — the share of instrument and staff time that is billable. Because a lab network carries heavy fixed costs (buildings, instruments, accreditation, quality-assurance staff), profit is highly sensitive to filling that capacity; incremental samples on already-built capacity drop a lot to the bottom line (operating leverage). When volumes fall, underused equipment pressures margins.
• Price per test and mix — routine, commoditized tests (basic water panels) carry thin margins; complex or newly regulated methods (PFAS, extractables/leachables for medical devices) carry rich ones.
• Recurring, regulation-mandated share of revenue — the prize. Testing that a law or permit requires on a schedule is non-discretionary and sticky, and it is what buyers pay the highest multiples for. Related watch-items: revenue per lab, customer concentration and renewal rates, acquisition contribution, and cash conversion.

Costs are dominated by skilled labor, then instrument capital (a single LC-MS/MS — liquid chromatography–mass spectrometry — unit runs into the hundreds of thousands of dollars), consumables, utilities, waste handling, and the quality/accreditation overhead needed to keep results legally defensible.

Profitability. Reported EBITDA (earnings before interest, taxes, depreciation, and amortization) margins across the sector generally run 12–20%, with the best-run global majors at 18–23%.[30] Accreditation, validated methods, trusted data, and customer-specific workflows create switching costs. Sector economics reward network density (a lab within reach of the customer wins on turnaround and freight), accreditation breadth (each accredited method is a small moat), and scale in overhead (spreading QA and instrument capex across more volume). Note: the federal figures do not provide capacity utilization, test pricing, sample volumes, lab margins, or capital spending — those come from company disclosures.

Growth comes two ways: organically (rising sample volumes, price increases, adding newly-required methods) and through bolt-on M&A — buying small labs and plugging them into the network. The global consolidators have done this at industrial scale: Eurofins alone made roughly 378 acquisitions between 2015 and 2025; SGS around 97 and Bureau Veritas around 61 over comparable spans.[30]

6. What drives demand

• Regulation — the single biggest driver. Environmental rules (Clean Water Act, Safe Drinking Water Act, air permits, contaminated-site cleanup), food-safety law, drug and medical-device rules, consumer-product safety, workplace safety, and building codes all mandate testing by accredited third parties. Demand rises with each new rule and each tightened limit.
• Emerging contaminants — the current wave. Per- and polyfluoroalkyl substances (PFAS, or "forever chemicals") are the standout: the EPA has set enforceable drinking-water limits, developed methods across environmental media (e.g., Method 1633A covering 40 PFAS compounds), and committed roughly $1 billion in 2026 to state-led PFAS water projects — driving a PFAS-testing market growing at a mid-teens annual rate off a ~$0.5 billion 2025 base.[23][24]
• Outsourcing. Many customers lack the equipment, accreditation, technical staff, or independence to perform all testing internally.
• Industrial and infrastructure capital spending. Construction volumes drive geotechnical and construction-materials testing (soil, concrete, steel); energy and heavy-industry capex drives NDT/asset-integrity inspection. This portion of demand is genuinely cyclical.
• Product complexity and new technology. Electric-vehicle batteries, semiconductors, data centers, connected devices, renewable-energy and hydrogen equipment, and medical devices each require more — and more sophisticated — testing and certification.
• Pharmaceutical and biotech development. Drug, biologic, and device developers outsource analytical, stability, microbiology, toxicology, and release testing.
• Trade and supply chains. Global sourcing generates continuous quality, safety, and compliance testing of imported goods and market-entry certification.
• Asset integrity, litigation, insurance, and ESG. NDT and materials analysis keep pipelines, aircraft, and power plants safe; liability exposure and voluntary sustainability claims add a discretionary layer on top of the mandated base.

7. Regulation

Regulation shapes this industry twice — as the source of demand and as the barrier to entry. Investors should distinguish lab accreditation, product certification, regulatory approval, customer-specific qualification, and voluntary marketing claims; a single lab may need several at once.

• Accreditation. The foundational credential is ISO/IEC 17025, the international standard for the technical competence of testing and calibration labs (ISO = International Organization for Standardization; IEC = International Electrotechnical Commission). Accreditation is granted method-by-method, not as a blanket guarantee. In the U.S. it is issued by the National Institute of Standards and Technology's NVLAP (National Voluntary Laboratory Accreditation Program) and by private accreditation bodies such as A2LA and ANAB.[25] Environmental labs additionally need NELAP (National Environmental Laboratory Accreditation Program) recognition under the TNI standard, often state-administered, plus specialty programs like DoD ELAP (Department of Defense Environmental Laboratory Accreditation Program) and state programs such as California's ELAP.[23]
• Mandated methods. Labs must run officially prescribed procedures — EPA methods (e.g., 533 and 537.1 for PFAS in drinking water; 1633A for PFAS in other media), Standard Methods, ASTM and AASHTO methods for construction materials, USP for pharmaceuticals, AOAC for food.[23] A lab can only sell a regulated test if it is accredited for that specific method — which is what makes each accreditation a competitive asset.
• Good Laboratory Practice. The Food and Drug Administration (FDA) requires GLP (Good Laboratory Practice) standards for nonclinical studies supporting regulated products, and imposes laboratory-control requirements on pharmaceutical manufacturing.[26]
• Product-safety recognition. For product certification, the Occupational Safety and Health Administration's NRTL (Nationally Recognized Testing Laboratory) program authorizes bodies such as UL and Intertek's ETL mark to certify electrical and other products for the U.S. market.[27]
• Federal contracting. The SBA's $19 million receipts ceiling defines which labs qualify as "small" for set-aside government work — a meaningful revenue channel for mid-sized environmental and materials labs.[3]

The net effect: accreditation and method mandates raise the cost of entry, protect incumbents, and make demand durable — but they also tie a lab's fortunes to the regulatory agenda and to agency budgets. State and local rules matter too, especially for water, air, building materials, food safety, and vehicle inspections.

8. Competitive dynamics and consolidation

By the federal numbers this is one of the most fragmented industries you will encounter. The four largest firms hold just 15.3% of revenue, the top eight 24.4%, the top twenty 37%, and even the top fifty only 49.8%.[2] The HHI (a standard concentration gauge where anything below 1,500 is considered unconcentrated) sits at 103 — near the floor.[2] No firm dominates; thousands compete regionally and by specialty. That said, national fragmentation does not mean every niche is competitive — specialized battery, aerospace, pharmaceutical, or certification work can carry high method-specific or local barriers.

Competition is less about owning the largest generic lab than about owning trusted capability in particular methods, geographies, customer industries, and regulatory regimes. The strongest advantages: accreditation and method breadth, scientific reputation and data integrity, fast reliable turnaround, sample-collection and logistics networks, certification marks / regulatory recognition, and the ability to serve multinational customers consistently.

That fragmentation is exactly why the sector is a consolidation engine. Global majors and PE platforms buy small labs to add methods, geography, and volume — the classic buy-and-build. Recent structural moves:

• Acuren merged with NV5 Global (a ~$941M-revenue engineering/testing firm) in August 2025 to form a >$2 billion North American TIC company, renamed TIC Solutions.[8]
• SGS and Bureau Veritas held, then abandoned, merger talks in January 2025 on what would have been a ~$33 billion combination — a reminder that even the giants are hunting scale.[28]
• Applus+ was taken private by TDR Capital and I Squared in 2024; Element sits inside Temasek.[14][15]

Deal activity is heavy and steady — well over 280 announced TIC transactions in 2025.[29] Valuations reflect the appeal: publicly traded TIC companies traded at a median of about 14.3× EV/EBITDA (enterprise value to EBITDA) in late 2025, while acquisitions have priced anywhere from single digits to high-teens multiples depending on growth, margin stability, and how regulation-locked the revenue is.[30] The main constraint is quality control: a roll-up that grows revenue but weakens scientific discipline — damaging accreditation, turnaround, or data integrity — can destroy value.

9. Risks

• Cyclicality of the industrial base. Construction-materials, geotechnical, and energy-NDT segments rise and fall with capital spending; a downturn in building, mining, or industrial capex hits volumes directly.
• Regulatory dependence cuts both ways. New rules create demand, but deregulation, weaker enforcement, delayed rulemaking, or cuts to agency budgets can shrink mandated testing.
• Labor. The industry runs on scarce, credentialed chemists, microbiologists, technicians, and inspectors; wage inflation and hiring shortfalls squeeze margins and cap growth.
• Commoditization and pricing pressure. Routine, high-volume tests are price-competitive; without a mix shift toward complex methods, margins erode.
• Capital intensity of new methods. Staying current (new instruments, new accreditations for methods like PFAS) requires ongoing capex ahead of the revenue.
• Quality, liability, and reputation. A lab's product is a trustworthy result. A missed defect, a contaminated sample, a chain-of-custody failure, or a false certification carries legal and reputational consequences out of proportion to the fee — and can trigger loss of accreditation, removing a lab from a market.
• Customer insourcing. Large manufacturers can pull testing back in-house when volume justifies it, removing work from the commercial market.
• Customer concentration. A single major manufacturer, government contract, or pharmaceutical client can represent substantial local revenue.
• Roll-up execution risk. For the acquisitive platforms, overpaying, excessive debt, weak integration, and goodwill impairment are real risks if organic growth or margins disappoint.
• Scope and foreign-market risk. Public-company results bundle inspection, certification, consulting, software, and non-U.S. operations that do not map cleanly to NAICS 541380; foreign-listed names add currency, political, and jurisdictional exposure.

10. How to invest, and the outlook

Public-market routes. Direct U.S.-listed exposure is limited but real: UL Solutions (ULS) for product-safety testing and certification, TIC Solutions (TIC) and Mistras (MG) for industrial NDT and asset integrity, and Montrose Environmental (MEG) for environmental testing (bundled with environmental services).[7][8][9][10] For broader, higher-margin exposure, the global majors — SGS, Bureau Veritas, Eurofins, Intertek (and Australia's ALS) — are the deepest pure-plays, reachable through ADRs or foreign lines.[11][12][13][16] There is no meaningful dedicated U.S. testing-lab ETF; investors get exposure through these individual names or diversified industrials/business-services funds. Start with exposure mapping, not ticker-picking: for each company separate lab testing from inspection, certification, advisory, software, diagnostics, and foreign operations, then examine organic growth, price versus volume, utilization, margins, cash conversion, capex, acquisition discipline, leverage, and end-market regulation. Compare on EV/EBITDA and free-cash-flow yield, adjusting for currency and business mix.

Private-market routes. This is where most of the action is. A deeply fragmented base, sticky regulation-driven revenue, and healthy margins make independent environmental, food-safety, pharmaceutical, and construction-materials labs prime buy-and-build targets; PE has been an aggressive, sustained buyer, and thousands of small labs remain unconsolidated.[30][29] Diligence should focus on accreditation scope and method validation, laboratory information management systems (LIMS), sample logistics and turnaround, customer retention and recurring-versus-project mix, employee retention, equipment condition and maintenance capex, environmental liabilities, normalized EBITDA, working capital, and debt capacity. The best target is usually a trusted specialist with repeat customers and a capability that is hard to replicate.

Near-term drivers to watch. The PFAS testing wave should be a multi-year tailwind as federal drinking-water limits phase toward compliance and new monitoring rules take effect.[23][24] Reshoring of manufacturing, semiconductor and battery build-outs, data-center construction, and infrastructure spending should support materials, geotechnical, and product testing. Against that, the industrial-cyclical segments remain hostage to the capex cycle, and the regulated core is only as strong as the political will to enforce the rules that mandate it.

Forward-looking judgment. The outlook is constructive but selective. Compliance, product complexity, environmental monitoring, safety requirements, and technology change should support long-term demand, but revenue will stay uneven across niches, and the best returns are more likely to come from specialized capabilities, disciplined consolidation, and high-quality execution than from indiscriminate exposure to the broad TIC label. The bottom line: testing labs are "trust plus throughput" businesses — the moat is not owning instruments, it is producing defensible results quickly, under recognized methods, for customers that cannot afford to be wrong. That structural case — non-discretionary demand, fragmentation ripe for consolidation, and durable margins — is what keeps both strategic and financial buyers paying up.

---

Sources

1. U.S. Census Bureau, County Business Patterns (2023), NAICS 541380 — employment, establishments, annual and first-quarter payroll. https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau, 2022 Economic Census, Concentration by Largest Firms, NAICS 541380 — receipts, firm count, concentration ratios (CR4/CR8/CR20/CR50), HHI. https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
3. U.S. Small Business Administration, Table of Small Business Size Standards (2023), NAICS 541380 = $19 million. https://www.sba.gov/document/support-table-size-standards
4. U.S. Census Bureau / NAICS, 2022 NAICS Definition, 541380 Testing Laboratories and Services (scope and exclusions). https://www.census.gov/naics/?input=541380&year=2022
5. U.S. Census Bureau, About the 2022 Economic Census and County Business Patterns Methodology (coverage of employer establishments; exclusion of government and self-employed). https://www.census.gov/programs-surveys/economic-census/year/2022/about.html
6. MarketsandMarkets / Aventis Advisors, U.S. and Global TIC market — SGS, Bureau Veritas and Intertek combined scale and share (2025). https://aventis-advisors.com/top-10-largest-testing-inspection-and-certification-companies-globally/
7. UL Solutions Inc., Full-Year 2024 Results (revenue ~$2.9B) and Form 10-K; controlled by UL Standards & Engagement. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001901440&type=10-K
8. Acuren Corporation, FY2024 Results and Acuren–NV5 Global Merger (2025); renamed TIC Solutions, Inc. https://www.businesswire.com/news/home/20250515498193/en/
9. Mistras Group, Inc. (NYSE: MG), 2024 revenue (~$0.72B) and profile. https://investors.mistrasgroup.com/financial-information/annual-reports
10. Montrose Environmental Group, Record Fourth Quarter and Full Year 2024 Results (Measurement & Analysis segment). https://www.prnewswire.com/news-releases/montrose-environmental-group-reports-record-fourth-quarter-and-full-year-2024-results-and-provides-strong-2025-guidance-302386522.html
11. Eurofins Scientific, Full-Year 2024 Results (North America ~38% of net sales; U.S. PFAS-testing leadership). https://www.businesswire.com/news/home/20250129893744/en/
12. SGS SA, 2024 Annual Results (sales CHF 6.794 billion). https://www.sgs.com/en/investor-relations
13. Bureau Veritas, 2024 Full-Year Results (revenue ~€6.3 billion). https://group.bureauveritas.com/investors/our-profile/key-figures
14. Temasek / Element Materials Technology, Temasek completes ~$7bn acquisition of Element (2022); Temasek portfolio holding. https://www.element.com/about-element/news/2022/07/05/element-announces-completion-of-its-acquisition-by-temasek
15. TDR Capital / I Squared Capital, Amber EquityCo takes Applus+ private (2024). https://www.tdrcapital.com/portfolio/applus/
16. ALS Limited (ASX: ALQ), Annual Report 2025 (commodities/geochemistry and environmental testing). https://www.alsglobal.com/en/investor-relations
17. Pace Analytical (Leonard Green & Partners; Aurora Capital co-investor), company profile. https://www.pacelabs.com/
18. DNV, Corporate Governance (Stiftelsen Det Norske Veritas foundation ownership). https://www.dnv.com/about/in-brief/corporate-governance/
19. TÜV SÜD, Corporate structure (TÜV SÜD e.V. 74.9% / Foundation 25.1%). https://www.tuvsud.com/en/about-us
20. TÜV Rheinland, Organisation and Bodies (TÜV Rheinland Berlin Brandenburg Pfalz e.V. sole shareholder). https://www.tuv.com/world/en/about-us/organisation-and-bodies/
21. DEKRA, Company / ownership (DEKRA e.V. association). https://www.dekra.com/en/dekra-at-a-glance/
22. NSF, About NSF (independent nonprofit). https://www.nsf.org/about-nsf
23. U.S. EPA, Clean Water Act and drinking-water PFAS analytical methods (533, 537.1, 1633A), drinking-water limits and 2026 funding, plus TNI/NELAP, A2LA, and DoD ELAP accreditation frameworks. https://www.epa.gov/cwa-methods/cwa-analytical-methods-and-polyfluorinated-alkyl-substances-pfas
24. MarketsandMarkets, PFAS Testing Market (~$0.49B in 2025 to ~$0.97B by 2030, ~14.5% CAGR). https://www.marketsandmarkets.com/Market-Reports/pfas-testing-market.asp
25. National Institute of Standards and Technology, About NVLAP (ISO/IEC 17025 accreditation). https://www.nist.gov/nvlap/about-nvlap
26. U.S. Food and Drug Administration, Good Laboratory Practice (GLP) — Bioresearch Monitoring. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/fda-bioresearch-monitoring-information
27. Occupational Safety and Health Administration, Nationally Recognized Testing Laboratory (NRTL) Program. https://www.osha.gov/nationally-recognized-testing-laboratory-program
28. SwissInfo, SGS and Bureau Veritas end ~$33bn merger talks (January 2025). https://www.swissinfo.ch/eng/business/sgs-bureau-veritas-merger-talks/
29. Consultancy.eu / Houlihan Lokey, TIC & Compliance M&A — 280+ announced transactions in 2025. https://www.consultancy.eu/news/13863/ma-in-testing-inspection-certification-and-compliance-sector-remains-upbeat
30. Aventis Advisors, TIC Company Valuations: Testing, Inspection, and Certification M&A Report (median ~14.3× EV/EBITDA; sector EBITDA margins; Eurofins/SGS/Bureau Veritas acquisition counts), 2025. https://aventis-advisors.com/tic-company-valuations/